A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Fimasartan (Primary) ; Olmesartan medoxomil; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms FAST
- Sponsors Boryung Pharmaceutical
- 03 Jul 2017 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.